4-Hydroxy-3-nitrobenzenearsonic acid (commonly 3-Nitro, or its generic, Roxarsone) was a FDA approved for increased rate of weight gain, improved feed efficiency, and improved pigmentation for growing chickens and growing turkeys. For increased rate of weight gain and improved feed efficiency for growing-finishing swine. Roxarsone is marketed as 3-Nitro by Zoetis, a former subsidiary of Pfizer now a publicly traded company. 3-Nitro is indicated for combination use with certain other medications as an effective aid in the prevention of coccidiosis, the most common infection in poultry. Roxarsone promotes angiogenesis in vivo, and a VEGF/VEGFR mechanism may be involved. In September 2013, the FDA announced that Zoetis and Fleming Laboratories would voluntarily withdraw current roxarsone, arsanilic acid, and carbarsone approvals, leaving only nitarsone approvals in place. In 2015 FDA withdraw the approval of using nitarsone in animal feeds. The ban will came into effect at the end of 2015. Roxarsone is banned in the European Union.